Teladoc price target lowered to $18 from $25 at RBC Capital

RBC Capital analyst Sean Dodge lowered the firm’s price target on Teladoc to $18 from $25 but keeps an Outperform rating on the shares. The company’s Integrated Care segment upside helped offset weakness in BetterHelp, where revenue missed the firm’s forecast and EBITDA margin came in near the low-end of guidance, the analyst tells investors in a research note. The number of paying BetterHelp users has also declined for a third consecutive quarter, but the management laid out plans to re-accelerate growth via innovating around all aspects of user acquisition, monetization, and retention, the firm added.